Phase III EF-14 Trial Shows Tumor Treating Fields Improve OS in Brain Cancer

Video
Conference|Society for NeuroOncology Annual Meeting

Results from the EF-14 trial which compared standard of care for glioblastoma plus or minus the tumor treating fields. 

Roger Stupp, MD, professor of oncology, University of Zurich, discusses the EF-14 trial which compared standard of care for glioblastoma plus or minus tumor treating fields with Optune. Median overall survival was 20.8 months for temozolomide plus Optune versus 16.0 months for temozolomide-alone (HR, 0.65; 95% CI, 0.54-0.79;P

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
Novel CAR T Therapy Earns FDA Breakthrough Status for Incurable Pediatric Brain Tumor

Novel CAR T Therapy Earns FDA Breakthrough Status for Incurable Pediatric Brain Tumor

Sabrina Serani
April 22nd 2025
Article

Read More

Recommendations for Treating Central Nervous System Cancers

Recommendations for Treating Central Nervous System Cancers

Nichole Tucker;Craig Horbinski, MD, PhD
July 14th 2023
Podcast

In season 4, episode 10 of Targeted Talks, Craig Horbinski, MD, PhD, reviews the clinical practice guidelines for central nervous system cancers.

Listen

Well-Tolerated TLX101 Shows Efficacy in Recurrent Glioma

Well-Tolerated TLX101 Shows Efficacy in Recurrent Glioma

Jordyn Sava
April 17th 2025
Article

Preliminary results from the phase 2 IPAX-Linz study show encouraging efficacy and a favorable safety profile for TLX101 in recurrent high-grade glioma.

Read More

FDA Approves IDE Application for Alpha DaRT in Recurrent Glioblastoma

FDA Approves IDE Application for Alpha DaRT in Recurrent Glioblastoma

Jordyn Sava
April 3rd 2025
Article

A pilot study will evaluate Alpha DaRT for the treatment of patients with recurrent glioblastoma.

Read More

VXM01 Plus Avelumab Shows Safety, Tolerability in Recurrent Glioblastoma

VXM01 Plus Avelumab Shows Safety, Tolerability in Recurrent Glioblastoma

Jordyn Sava
March 27th 2025
Article

Early results show that the combination of VXM01 plus avelumab demonstrated tolerable safety in recurrent glioblastoma.

Read More

Mirvetuximab Shows Lasting Survival Benefit in Resistant Ovarian Cancer

Mirvetuximab Shows Lasting Survival Benefit in Resistant Ovarian Cancer

Jordyn Sava
March 18th 2025
Article

Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment paradigms in ovarian cancer.

Read More